|Main uses||Multiple sclerosis|
|Side effects||Infusion reaction, upper respiratory tract infection|
|Typical dose||450 mg|
|Chemical and physical data|
|Molar mass||144504.31 g·mol−1|
Ublituximab, sold under the brand name Briumvi, is a medication used to treat multiple sclerosis. Specifically it is used for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is given by injection into a vein.
Common side effects include infusion reactions and upper respiratory tract infections. Other side effects may include infections and low immunoglobulins. Use during pregnancy may harm the baby. It is a monoclonal antibody directed against CD20.
Ublituximab was approved for medical use in the United States in 2022. In 2023 it received a positive opinion by regulators in Europe. In the United States it costs about 64,000 USD per year as of 2023.
Ublituximab is used to treat relapsing forms of multiple sclerosis. It decreases relapses per year by about 50%.
The initial doses are generally 150 mg followed two weeks later by 450 mg. Further doses of 450 mg are than given every 24 weeks.
Researchers demonstrated the efficacy of ublituximab in two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in participants with relapsing forms of multiple sclerosis treated for 96 weeks. Participants were randomized to receive either ublituximab or teriflunomide, the active comparator. The primary outcome of both studies was the annualized relapse rate over the treatment period. In both studies, ublituximab significantly lowered the annualized relapse rate compared to teriflunomide.
Society and culture
Ublituximab is the international nonproprietary name (INN).
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 "Briumvi- ublituximab injection, solution, concentrate". DailyMed. 19 January 2023. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
- ↑ 2.0 2.1 "Briumvi: Pending EC decision". European Medicines Agency. 28 March 2023. Archived from the original on 8 April 2023. Retrieved 11 April 2023.
- ↑ "Ublituximab-Xiiy". Archived from the original on 11 April 2023. Retrieved 11 April 2023.
- ↑ 4.0 4.1 4.2 4.3 4.4 "FDA Roundup: December 30, 2022". U.S. Food and Drug Administration (FDA) (Press release). 30 December 2022. Archived from the original on 30 December 2022. Retrieved 30 December 2022. This article incorporates text from this source, which is in the public domain.
- ↑ World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). hdl:10665/74683.
- Babiker HM, Glode AE, Cooke LS, Mahadevan D (April 2018). "Ublituximab for the treatment of CD20 positive B-cell malignancies". Expert Opinion on Investigational Drugs. 27 (4): 407–412. doi:10.1080/13543784.2018.1459560. PMID 29609506. S2CID 4775126.
- Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, et al. (November 2019). "Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia". Blood. 134 (21): 1811–1820. doi:10.1182/blood.2019002118. PMC 7042665. PMID 31558467.
- Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, et al. (August 2022). "Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis". The New England Journal of Medicine. 387 (8): 704–714. doi:10.1056/NEJMoa2201904. PMID 36001711. S2CID 251808946.
- Pages using duplicate arguments in template calls
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Chemicals that do not have a ChemSpider ID assigned
- Monoclonal antibodies
- Orphan drugs